Also known as Afinitor
Everolimus (RAD-001) is the 40-O-(2-hydroxyethyl) derivative of sirolimus and works similarly to sirolimus as an inhibitor of mammalian target of rapamycin (mTOR).
Source: WikipediaPatients are most commonly prescribed everolimus to treat kidney cancer, rabies, pick disease, and blastomycosis.
Critical Interactions
Significant Interactions
Patients taking everolimus most commonly experience side effects like redness in ear, otitis media, and skin rash.